


Non-Malignant Summary Slides

Table of Contents


Slide #	Slide Category
2	Table of Contents
3-18	Overall Non-Malignant Disease
19-26	Aplastic Anemia
27-34	Sickle Cell Disease
35-39	Thalassemia
40-44	Inherited Bone Marrow Failure
45-49	Metabolic Disease
50-54	Autoimmune Disease
55-58	SCID
59-63	Non-SCID Primary Immune Deficiency
64-68	HLH and Other Histiocytic Disorders

Overall non-malignant diseases


AlloHCTs for non-malignant diseases, US, by age group




AlloHCT for overall non-malignant diseases, US, by donor type




AlloHCTs for overall non-malignant diseases, US, by donor type




AlloHCTs for overall non-malignant diseases, US, by donor type, pediatrics




AlloHCTs for overall non-malignant diseases, US, by donor type, pediatrics




AlloHCTs for overall non-malignant diseases, US, by donor type, adults




AlloHCTs for overall non-malignant diseases, US, by donor type, adults




Comorbidity index in alloHCTs for non-malignant diseases, US, by recipient age, adults, 2014–2024




Youth comorbidity index in alloHCTs for non-malignant diseases, US, by indication, pediatrics, 2014–2024




GVHD prophylaxis for non-malignant HCTs, US, by year




GVHD prophylaxis for non-malignant HCTs, US, by indication, 2014-2024



Gene therapies for non-malignant diseases by indication, US, 2018-2024




Trends in survival after alloHCT for non-malignant diseases, US, 2010-2023




Causes of death for overall non-malignant disease, alloHCT, pediatrics, US, 2019-2024

Died within 100 days



N = 176

Died at or beyond 100



N = 217


- Primary disease
- Graft rejection
- GVHD
- Hemorrhage
- Infection
- Secondary malignancy
- Organ failure
- Other
- Not reported

Causes of death for overall non-malignant disease, alloHCT, adults, US, 2019-2024


Died within 100 days

Died at or beyond 100 days

Total HCTs
N = 2163



N = 137



N = 204


- Primary disease
- Graft rejection
- GVHD
- Hemorrhage
- Infection
- Secondary malignancy
- Organ failure
- Other
- Not reported

Aplastic anemia


AlloHCTs for aplastic anemia, US, 2014-2024




AlloHCTs for aplastic anemia, US, by recipient age, 2014-2024




AlloHCTs for aplastic anemia, US, by donor type, 2014-2024




Relative proportion of alloHCTs for aplastic anemia, US, by donor type



Survival after alloHCT for aplastic anemia, US, 2014-2023, by age group




Survival after alloHCT for aplastic anemia, US, 2014-2023, by donor type



Causes of death for aplastic anemia, all ages, alloHCT, US, 2019-2024

Died within 100 days



N = 113

■ Primary disease

■ Secondary malignancy

■ Graft rejection

■ Organ failure

■ GVHD


■ Other

■ Hemorrhage

■ Not reported

■ Infection


Died at or beyond 100 days




N = 134

Sickle cell disease


AlloHCTs for sickle cell disease, US, 2014-2024



AlloHCTs for sickle cell disease, US, by recipient age, 2014-2024



AlloHCTs for sickle cell disease, US, by donor type, 2014-2024




Relative proportion of alloHCTs for sickle cell disease, US, by donor type


MRD MUD Mismatched Related donor MMUD UCB



Survival after alloHCT for sickle cell disease, US, 2014-2023, by age group




Survival after alloHCT for sickle cell disease, US, 2014-2023, by donor type




Causes of death for sickle cell disease, all ages, alloHCT, US, 2019-2024

Died within 100 days



N = 12

Died at or beyond 100 days




N = 48


- Primary disease
- Graft rejection
- GVHD
- Hemorrhage
- Infection
- Secondary malignancy
- Organ failure
- Other
- Not reported

Thalassemia


AlloHCTs for thalassemia, US, 2014-2024




Survival after alloHCT for thalassemia, US, 2014-2023, by age group



Survival after alloHCT for thalassemia, US, 2014-2023, by donor type




Survival after gene therapy for sickle cell disease and thalassemia, US, 2018-2024




Inherited bone marrow failure


AlloHCTs for inherited bone marrow failure, US, 2014-2024



Survival after alloHCT for inherited bone marrow failure, US, 2014-2023



Survival after alloHCT for inherited bone marrow failure, US, 2014-2023, by donor type





Causes of death for inherited bone marrow failure, all ages, alloHCT, US, 2019-2024

Died within 100 days

Died at or beyond 100 days


Total HCTs
N = 524




- Primary disease
- Graft rejection
- GVHD
- Hemorrhage
- Infection
- Secondary malignancy
- Organ failure
- Other
- Not reported

Metabolic disease


AlloHCTs for metabolic disease, US, 2014-2024



Survival after alloHCT for metabolic disease, US, 2014-2023, by age group



Survival after alloHCT for metabolic disease, US, 2014-2023, by donor type




Causes of death for metabolic disease, all ages, alloHCT, US, 2019-2024


Died within 100 days

Died at or beyond 100 days

Total HCTs
N = 383



N = 34




N = 32


- Primary disease
- Graft rejection
- GVHD
- Hemorrhage
- Infection
- Secondary malignancy
- Organ failure
- Other
- Not reported

Autoimmune disease


AlloHCTs for autoimmune disease, US, 2014-2024




AlloHCTs for autoimmune disease, US, by recipient age, 2014-2024



Cell therapy for autoimmune disease, US, 2019-2024




Survival after alloHCT for autoimmune disease, US, 2014-2023




SCID


AlloHCTs for SCID, US, 2014-2024



Survival after alloHCT for SCID, US, 2014-2023, by age group



Survival after alloHCT for SCID, US, 2014-2023, by donor type




Non-SCID primary immune deficiency


AlloHCTs for non-SCID primary immune deficiency, US, 2014-2024



Survival after alloHCT for non-SCID primary immune deficiency, US, 2014-2023




Survival after alloHCT for non-SCID primary immune deficiency, US, 2014-2023, by donor type




Causes of death for SCID and non-SCID primary immune deficiencies, all ages, alloHCT, US, 2019-2024

Died within 100 days



N = 77

Died at or beyond 100 days



N = 106


- Primary disease
- Graft rejection
- GVHD
- Hemorrhage
- Infection
- Secondary malignancy
- Organ failure
- Other
- Not reported

HLH and other histiocytic disorders


AlloHCTs for HLH and other histiocytic disorders, US, 2014-2024



Survival after alloHCT for HLH and other histiocytic disorders, US, 2014-2023



Survival after alloHCT for HLH and other histiocytic disorders, US, 2014-2023, by donor type




Causes of death for HLH and other histiocytic disorders, all ages, alloHCT, US, 2019-2024


Died within 100 days

Died at or beyond 100 days

**Total HCTs
N = 327**



N = 43



N = 41

- | | | | | |
|------------------------|-------------------|---------|----------------|-------------|
| ■ Primary disease | ■ Graft rejection | ■ GVHD | ■ Hemorrhage | ■ Infection |
| ■ Secondary malignancy | ■ Organ failure | ■ Other | ■ Not reported | |